(Total Views: 851)
Posted On: 11/01/2018 8:54:59 AM
Post# of 503
Many will regret not investing in UEEC! A DEAL THAT WILL HAPPEN!
Review of Strategic Alternatives
https://www.etrade.wallst.com/v1/stocks/news/...ls=US;UEEC
In connection with the FDA PMA Class III approval process for HemoStyp, UHP has been contacted by several medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who have expressed an interest in the Company's products and business strategy. In response to these inbound contacts, and to maximize shareholder value, the Company's board of directors has determined to conduct a review of strategic alternatives, which include a potential sale of the Company, joint venture or other commercial partnership, or a standalone growth plan. To assist in this review, the Company has retained Société Générale to serve as financial advisor to the Company. The Company notes that there is no assurance this review will result in any transaction, and it will not reveal details of developments related to its review unless and until the board has approved a specific transaction or otherwise determined that further disclosure is appropriate.
Review of Strategic Alternatives
https://www.etrade.wallst.com/v1/stocks/news/...ls=US;UEEC
In connection with the FDA PMA Class III approval process for HemoStyp, UHP has been contacted by several medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who have expressed an interest in the Company's products and business strategy. In response to these inbound contacts, and to maximize shareholder value, the Company's board of directors has determined to conduct a review of strategic alternatives, which include a potential sale of the Company, joint venture or other commercial partnership, or a standalone growth plan. To assist in this review, the Company has retained Société Générale to serve as financial advisor to the Company. The Company notes that there is no assurance this review will result in any transaction, and it will not reveal details of developments related to its review unless and until the board has approved a specific transaction or otherwise determined that further disclosure is appropriate.
(0)
(0)Scroll down for more posts ▼
